European Auto Stocks Rise as EU-China Trade Deal Targets Hybrid Imports 
Nvidia’s China AI Chip Market Share Falls to 34% as Huawei Gains Ground 
US Dollar Rises for Fourth Week as Fed Rate Hike Bets Grow 
Nasdaq Falls as Oil Prices Surge Ahead of Bank Earnings 
Global Stocks Mixed as Oil Falls Ahead of US Earnings 
Oil Prices Surge Above $106 After Deadly Saudi Airport Attack 
Philippines Current Account Deficit Seen at $19.1 Billion in 2026 
Russia Approves Sberbank for Crypto Exchange Services 
Moonshot AI Executives Seek Settlement Ahead of Hong Kong IPO 
Apple Supplier Luxshare Faces US Patent Probe, Sees Limited Impact 
S&P 500 Rally Masks Losses for Over 40% of Stocks in 2026 
Asian Currencies Steady as Dollar Nears 18-Month High Ahead of US CPI 
Epic Games Delays Disney Shooter, Shifts to AI-First Development 
Most Americans Oppose Election Betting on Prediction Markets, Poll Finds 
Deutsche Bank CEO Urges Faster German Economic Reforms 
Gold Prices Rebound as Dollar Weakens Ahead of US Inflation Data 
Add as a preferred source on Google
Samsung Electronics’s executive chairman, Lee Jae Yong, has been holding meetings with leaders of the leading biopharmaceutical and biotechnology companies to forge joint ventures or enter into partnership deals.
The Samsung Electronics chief reportedly met up with global executives of some leading brands in the biotech and biopharma industry, including Johnson & Johnson’s chief executive officer, Joaquin Duato; Biogen’s chief, Christopher Viehbacher; Bristol Myers Squibb’s CEO, Giovanni Caforio; Kevin Ali, Organon’s CEO; and Noubar Afeyan of Flagship Pioneering.
Lee held meetings with them during his recent trip to the United States. Korea Joongang Daily reported that the Samsung leader has a goal of securing partnership agreements with them as he is seeing the biopharma and biotech fields as the company’s new growth drivers.
The Samsung chairman also commented during his trip, "The starting point is not important, but bold and persistent challenges set victory apart from defeat. Let us continue the success story of chips with bio."
In any case, Lee Jae Yong is trying to get contracts for the company’s CMDO arm, Samsung Biologics, which is currently the largest contract manufacturing and development organization in the world based on production capacity.
While it is a latecomer in this market, Samsung Biologics is doing fairly well since it was first established in 2011. Samsung Electronics owns 31.22% of shares in its affiliate CMDO firm.
"The bio-industry is a field with high barriers to entry, requiring not only production technology and R&D capabilities but also trust and reputation building for long-term collaboration,” The Korea Times quoted Samsung as saying in a statement regarding the chairman's move to seek collaborations with US bio companies. “Lee's wide global network is expected to serve as a lever for Samsung's bio business to expand collaboration with big pharmaceutical companies and create future growth opportunities."
